Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Urolithin A and ALS: Pulling Mitochondrial Levers

Original source

Urolithin A and ALS: Pulling Mitochondrial LeversCuralysis · 5 January 2026 (opens in a new tab)

The author says they recently added urolithin A to their personal supplement regimen, while stressing that it is not a cure or medical advice. The blog describes evidence from ALS laboratory and animal models involving mitochondrial quality control, but says there are no completed human trials of urolithin A in ALS.

Why this matters

This may interest people considering supplements aimed at mitochondrial function, but it does not currently support urolithin A as an ALS treatment. The reported ALS findings are preclinical, and human studies cited in the blog involved ageing and muscle health rather than ALS.

Limitations and context

This is a first-party blog and personal account, not primary ALS research or clinical guidance. The blog reports animal and laboratory findings and cites human studies in other populations, but does not provide evidence from completed human ALS trials. It also does not establish that urolithin A slows ALS or is safe for every person or medication combination.

Summarised by Compass 9 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?